Actinium Pharmaceuticals Inc. selects Zevacor Pharma to conduct clinical trial of Iomab-B

Actinium Pharmaceuticals announced this week its selection of Zevacor Pharma Inc. as the producer and supplier of Iomab-B for its Phase III clinical trial.

Zevacor Pharma, formerly IBA Molecular North America Inc., will manufacture, test and release the medication for the SIERRA trial.

"The selection of Zevacor marks an important milestone for our Iomab-B program and complements the capabilities of our clinical development team and contract research organization, Medpace," Executive Chairman Sandesh Seth said. "Actinium and our partners are intensely focused on the pivotal Phase 3 SIERRA trial and we are confident in our capabilities. We look forward to initiating the SIERRA trial and enrolling patients that can benefit from Iomab-B and a bone marrow transplant."

The Phase III trial will be focused on patients over age 55 with Acute Myeloid Leukemia (AML). The trial will enroll 150 patients.

Iomab-B was developed as a radioimmunotherapy induction and conditioning agent that will be used before a bone marrow transplant. It consists of BC8, a monoclonal antibody and iodine-131 radioisotope. The BC8 takes the radioactive isotope directly to the cancer and bone marrow and avoids damaging healthy tissues.